Pharmeasy company logo

Pharmeasy Share Price

PHYSICAL

PUBLIC LIMITED

Price Chart

High

₹51

Low

₹5.08

Return

-87.10%

Buy Sell Pharmeasy Unlisted Shares

As of November 15, 2026, API Holdings (Pharmeasy) Unlisted Shares are available at ₹6.58 per share, with a face value of ₹1.00 per share, a 52-week high of ₹9.00 and a 52-week low of ₹5.00. The minimum lot size is 2500 shares, and the shares can be held in dematerialised form through NSDL and CDSL.

ISIN

info icon

INE0DJ201029

Face Value

info icon

1

Total Shares

info icon

17,03,24,95,304

Market Cap

info icon

11,207.38 Cr

Profit After Tax

info icon

-1,572.39 Cr

Total Revenue

info icon

5,898.46 Cr

P/E

info icon

-7.13

P/B

info icon

1.46

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Micro Cap

Cashflow - Operations

info icon

-223.53 Cr

About Pharmeasy

PharmEasy is an Indian digital healthcare platform associated with API Holdings Limited, a company operating across online pharmacy services, pharmaceutical distribution, hospital supplies, diagnostics and healthcare technology. Through its app and website, PharmEasy connects consumers with medicines, healthcare products, diagnostic tests and other healthcare services.

PharmEasy provides online healthcare services, including home delivery of prescription and over-the-counter (OTC) medicines, nutraceuticals, wellness products, diagnostic test bookings with home sample collection, and access to teleconsultation and other digital healthcare services through its app and website.

Businesses and Subsidiaries of AP​I Holdings

API Holdings has built a broader healthcare network that serves consumers, pharmacies, doctors and hospitals. Its key businesses include:

  • PharmEasy: The consumer-facing digital healthcare marketplace for online medicine orders, healthcare products and diagnostic test bookings.

  • Ascent and Retailio: Ascent focuses on pharmaceutical distribution, while Retailio is its technology platform that connects pharmacies with pharmaceutical suppliers and supports digital ordering and inventory management.

  • Aknamed: A healthcare supply business that provides medicines, surgical products, medical devices and other medical supplies to hospitals and healthcare institutions.

  • Thyrocare Technologies Limited: A diagnostic services company acquired by API Holdings in 2021. It provides pathology testing and other diagnostic services to consumers, hospitals, laboratories and healthcare partners.

  • Docon: A digital healthcare technology business offering software and tools for doctors and clinics, including electronic medical records and practice management. API Holdings has announced a scheme to merge Docon Technologies with API Holdings.

  • Marg: A software business serving retailers and distributors through enterprise resource planning (ERP), billing, inventory management and business management tools. API Holdings acquired a stake in Marg as part of its expansion into healthcare technology.​

Investors researching PharmEasy unlisted shares should understand that the investment relates to API Holdings Limited, the parent company associated with the PharmEasy business, rather than a separately listed PharmEasy entity. Its wider business operations include pharmaceutical distribution, hospital supplies, diagnostics and healthcare technology.

Also Read: Who Owns PharmEasy? Current Ownership of API Holdings

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Pharmeasy Media

PharmEasy Parent API Holdings Raises ₹1,700 Crore, Pledges 61% Stake in Thyrocare as Collateral

PharmEasy Parent API Holdings Raises ₹1,700 Crore, Pledges 61% Stake in Thyrocare as Collateral

24 Sep 2025

• Angel One

PharmEasy re-enters TV with diagnostics campaign

PharmEasy re-enters TV with diagnostics campaign

04 May 2025

• Afaqs

PharmEasy sets stage for IPO return with new strategy, boosted cash flow

PharmEasy sets stage for IPO return with new strategy, boosted cash flow

20 Jan 2025

• Business Standard

Frequently Asked Question (FAQs)

The annual report of Pharmeasy Ltd is available in the annual report section.
Lock-in period of Pharmeasy Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Pharmeasy Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Pharmeasy Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.
Yes, buying and selling of unlisted shares in India is 100% legal.

Pharmeasy

₹ 6.58